KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Free Cash Flow (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Free Cash Flow for 15 consecutive years, with $19.4 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 56.02% to $19.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.0 million through Dec 2025, down 73.14% year-over-year, with the annual reading at $46.0 million for FY2025, 73.14% down from the prior year.
  • Free Cash Flow for Q4 2025 was $19.4 million at Supernus Pharmaceuticals, up from -$61.8 million in the prior quarter.
  • The five-year high for Free Cash Flow was $71.4 million in Q2 2022, with the low at -$61.8 million in Q3 2025.
  • Average Free Cash Flow over 5 years is $28.6 million, with a median of $36.0 million recorded in 2021.
  • The sharpest move saw Free Cash Flow skyrocketed 1315.47% in 2023, then tumbled 215.89% in 2025.
  • Over 5 years, Free Cash Flow stood at $48.8 million in 2021, then tumbled by 43.13% to $27.7 million in 2022, then skyrocketed by 62.25% to $45.0 million in 2023, then decreased by 1.78% to $44.2 million in 2024, then tumbled by 56.02% to $19.4 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at $19.4 million, -$61.8 million, and $58.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.